Newsletter | May 3, 2021

05.03.21 -- From Aha Moment To $10 Billion Biopharma

May Issue Articles
Got Your Zoom On?

The majority of my interviews have been over the phone. As for how many interviews for feature articles I’ve conducted via Zoom, the number is exactly two — both appearing in this issue.

From Aha Moment To $10 Billion Biopharma

In 2012, Neil Kumar, Ph.D., read an article in Nature Biotechnology and was so inspired by the paper’s theories on drug discovery and development that he eventually decided to quit his job and start his own biopharma called BridgeBio.

Interest In Hybrid Trials Increases

While outsourcing respondents currently hold mixed opinions on conducting hybrid trials, over two-thirds either currently use or plan to use them in the next two years.

Special Edition #2: Biopharma And The Management Of Wall St. During A Pandemic

Three CEOs of publicly traded biopharmaceutical companies discuss how they are leading their organizations, while also managing the expectations of Wall St. during the COVID-19 pandemic.

Web-Exclusive Content
The Art Of Coaching And Mentoring In Life Sciences Manufacturing

Tunnell Consulting’s Edgar Guerzon often coaches and mentors manufacturing staff on industry expectations and best practices. Here are some of his views on this “art” and how it provides real value during a client engagement. 

May 2021 Digital Edition

Inside you will find more on:

  • An Industry Outsider Becomes Biopharma CEO
  • Biosecurity
  • Gender Parity In Biotech
  • COVID-19 Drug Development

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.